DE69228098T2 - Verfahren zur Synthese von stabiler, einzelsträndiger cDNS in Eukaryoten durch Transfektion mit einem bakteriellen "Retron" enthaltenden Vektor und der verwendete Vektor - Google Patents

Verfahren zur Synthese von stabiler, einzelsträndiger cDNS in Eukaryoten durch Transfektion mit einem bakteriellen "Retron" enthaltenden Vektor und der verwendete Vektor

Info

Publication number
DE69228098T2
DE69228098T2 DE69228098T DE69228098T DE69228098T2 DE 69228098 T2 DE69228098 T2 DE 69228098T2 DE 69228098 T DE69228098 T DE 69228098T DE 69228098 T DE69228098 T DE 69228098T DE 69228098 T2 DE69228098 T2 DE 69228098T2
Authority
DE
Germany
Prior art keywords
dna
gene
retron
msr
msd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69228098T
Other languages
German (de)
English (en)
Other versions
DE69228098D1 (de
Inventor
Masayori Bridgewater Nj 08807 Inouye
Sumiko Bridgewater Nj 08807 Inouye
Shohei Misato.Shi Saitama Miyata
Atsushi Uji-Shi Kyoto-Fu Ohshima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Rutgers Health
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of DE69228098D1 publication Critical patent/DE69228098D1/de
Application granted granted Critical
Publication of DE69228098T2 publication Critical patent/DE69228098T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69228098T 1991-08-30 1992-08-28 Verfahren zur Synthese von stabiler, einzelsträndiger cDNS in Eukaryoten durch Transfektion mit einem bakteriellen "Retron" enthaltenden Vektor und der verwendete Vektor Expired - Fee Related DE69228098T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/753,110 US5436141A (en) 1989-02-24 1991-08-30 Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products

Publications (2)

Publication Number Publication Date
DE69228098D1 DE69228098D1 (de) 1999-02-18
DE69228098T2 true DE69228098T2 (de) 1999-07-01

Family

ID=25029201

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228098T Expired - Fee Related DE69228098T2 (de) 1991-08-30 1992-08-28 Verfahren zur Synthese von stabiler, einzelsträndiger cDNS in Eukaryoten durch Transfektion mit einem bakteriellen "Retron" enthaltenden Vektor und der verwendete Vektor

Country Status (5)

Country Link
US (1) US5436141A (enExample)
EP (1) EP0532380B1 (enExample)
JP (1) JP3140206B2 (enExample)
CA (1) CA2075515C (enExample)
DE (1) DE69228098T2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017737A (en) * 1989-02-24 2000-01-25 The University Of Medicine And Denistry Of New Jersey E. coli msDNA synthesizing system, products and uses
US5849563A (en) * 1989-02-24 1998-12-15 The University Of Medecine And Dentistry Of New Jersey Eukaryotes expressing single stranded hybrid molecules
US5780269A (en) * 1989-02-24 1998-07-14 The University Of Medicine And Denistry Of New Jersey Hybrid molecules
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
EP0673382A4 (en) 1992-12-09 1995-12-20 Jeffrey E Miller METHODS AND COMPOSITIONS FOR PERFORMING SYNTHESIS OF cDNA.
US5366690A (en) * 1993-06-18 1994-11-22 Combustion Engineering, Inc. Zirconium alloy with tin, nitrogen, and niobium additions
US20070160581A1 (en) * 1994-04-29 2007-07-12 Cytogenix, Inc. Production of ssDNA in vivo
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ES2374534T3 (es) 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation Control de la expresión de genes.
AU2004205192B2 (en) * 1998-10-09 2007-09-20 Cytogenix, Inc. Production of ssDNA in vivo
WO2000022113A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. ENZYMATIC SYNTHESIS OF ssDNA
CA2345936A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. Production of ssdna in a cell
DE69933382T2 (de) * 1998-10-09 2007-08-30 Cytogenix, Inc., Houston Herstellung von ssdna innerhalb der zelle
US20030082800A1 (en) * 1998-10-09 2003-05-01 Cytogenix, Inc. In vivo ssDNA expression vectors for altering gene expression
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7419964B2 (en) * 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
IL161100A0 (en) 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
AU2011253686C1 (en) * 2001-09-28 2014-04-03 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Micro-RNA molecules
US20050260588A1 (en) * 2002-05-01 2005-11-24 Conrad Charles A In vivo ssdna expression vectors for altering gene expression
WO2003093424A2 (en) * 2002-05-01 2003-11-13 Cytogenix, Inc. In vivo ssdna expression vectors for altering gene expression
EP1517992B1 (en) * 2002-06-05 2013-08-21 Her Majesty the Queen in Right of Canada, as represented by the Minister of Agriculture and Agri-Food Retrons for gene targeting
US20040248101A1 (en) * 2003-06-03 2004-12-09 Cytogenix, Inc. Identification of novel antibacteria agents by screening the single-stranded DNA expression library
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
KR20250035034A (ko) 2017-09-15 2025-03-11 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 Rna 분자
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US11866728B2 (en) 2022-01-21 2024-01-09 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023183588A1 (en) * 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132309A3 (en) * 1983-06-27 1985-12-27 The Board Of Trustees Of The Leland Stanford Junior University Novel regulatable eukaryotic promoter element
US5079151A (en) * 1989-02-24 1992-01-07 University Of Medicine And Dentistry Of New Jersey Production of branched RNA-linked multi-copy single-stranded DNA using permeabilized cells

Also Published As

Publication number Publication date
DE69228098D1 (de) 1999-02-18
EP0532380B1 (en) 1999-01-07
CA2075515C (en) 2005-11-01
JP3140206B2 (ja) 2001-03-05
US5436141A (en) 1995-07-25
EP0532380A2 (en) 1993-03-17
JPH06217776A (ja) 1994-08-09
CA2075515A1 (en) 1993-03-01
EP0532380A3 (enExample) 1994-05-04

Similar Documents

Publication Publication Date Title
DE69228098T2 (de) Verfahren zur Synthese von stabiler, einzelsträndiger cDNS in Eukaryoten durch Transfektion mit einem bakteriellen "Retron" enthaltenden Vektor und der verwendete Vektor
DE3486053T3 (de) Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
DE69425903T2 (de) Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
DE69319180T2 (de) Einstufiges Amplifikationsverfahren für RNS
DE60221801T3 (de) Cpg-freie synthetische gene und bakterielle plasmide
DE69303712T2 (de) Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz
EP1798285B1 (de) Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE3852539T3 (de) Ribozyme.
DE3111405C2 (enExample)
DE69126311T2 (de) Therapeutische zusammensetzungen auf der basis von ribozymen
DE3750288T2 (de) T7-DNS-Polymerase.
DE19631919C2 (de) Anti-Sinn-RNA mit Sekundärstruktur
DE60116506T9 (de) Methoden und reagenzien für molekulares klonieren
DD284692A5 (de) Verfahren zur herstellung prozessiver dna-polymerase
DE60207601T2 (de) Methode für die in vitro synthese von kurzen dobbelsträngigen rnas
DE69233106T2 (de) Verfahren zur Herstellung von Einzelsträndigen "stem-loop" DNS
DE69118809T2 (de) Erhöhte Produktion von thermus aquaticus DNA Polymerase in E. coli
EP0967274A2 (de) Verfahren zur Reinigung von kovalent geschlossenen DNA-Molekülen
DD254211A5 (de) Verfahren zur herstellung von plypeptiden
DE69232768T2 (de) Einzelsträngige hybride DNS-RNS Moleküle und Methoden zur Herstellung
DE69013811T2 (de) Verfahren zur Herstellung von antiviralem Protein unter Benützung von E.coli-Transformant, das Gen, das für dieses Protein kodiert und E.coli-Vektor benützt in diesem Verfahren.
Daniels et al. Characterization of a third major SINE family of repetitive sequences in the galago genome
DE69231143T2 (de) Spezifische Nukleotidsequenz enthaltender Masernvirusvakzinstamm und Verfahren zu seiner absoluten Identifizierung
DE69332514T2 (de) Transformation von Phaffia Rhodozyma
US20220396798A1 (en) Novel mrna composition and production method for use in anti-viral and anti-cancer vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee